Last reviewed · How we verify
Placebo soybean oil
Placebo soybean oil is a pharmacologically inert substance used as a control in clinical trials.
At a glance
| Generic name | Placebo soybean oil |
|---|---|
| Sponsor | Montreal Heart Institute |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
It does not have any therapeutic effect and is used to compare the efficacy of active treatments. Soybean oil is a common vehicle used in injectable formulations.
Approved indications
Common side effects
Key clinical trials
- Heart & Health Study (NA)
- NUTRIBRAIN: Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER) (NA)
- Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression (PHASE2)
- Omega-3 Supplementation in Systemic Lupus Erythematosus (NA)
- Efficacy and Safety of Tocotrienols in CADASIL (PHASE2)
- Omega-3, Autism Spectrum Disorder (ASD) (NA)
- Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression (NA)
- A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo soybean oil CI brief — competitive landscape report
- Placebo soybean oil updates RSS · CI watch RSS
- Montreal Heart Institute portfolio CI